Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women

PurposeTo evaluate the cost-effectiveness of adding ribociclib to endocrine therapy for pre/perimenopausal women with hormone receptor-positive (HR+), human epidermal receptor 2-negative (HER2-) advanced breast cancer from the US payer perspective.MethodsA partitioned survival analysis model with th...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Eunae Jeong, Changjun Wang, Leslie Wilson, Lixian Zhong
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2021-05-01
Serie:	Frontiers in Oncology
Soggetti:	breast cancer CDK4/6 inhibitor cost-effectiveness partitioned survival analysis ribociclib pre/perimenopausal
Accesso online:	https://www.frontiersin.org/articles/10.3389/fonc.2021.658054/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!